Figure 5. HOTAIRM1 silencing inhibits glioma cell proliferation, migration, invasion, and EMT and increases sensitivity to TMZ in vitro. (A) Cell proliferation after transfection of cells with si-HOTAIRM1-1 and -2, as determined with the CCK-8 assay. (B) Migration and invasion in U87 and LN229 cells evaluated with transwell assays. (C) Western blot analysis of E-cadherin (epithelial marker) and vimentin (mesenchymal marker) expression following HOTAIRM1 knockdown; β-actin served as a loading control. (D) Prognostic value of radiochemotherapy compared with radiotherapy alone in high- and low-exp groups. (E) Viability of U87 and LN229 cells transfected with siRNA against HOTAIRM1 (si-HOTAIRM1) or negative control siRNA (si-NC) following TMZ treatment at indicated doses. Values represent mean ± SD (n = 3 biological replicates). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (Student’s t test).